SomaLogic, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SomaLogic, Inc. SomaLogic, Inc. (SLGC) operates as a protein biomarker discovery and clinical diagnostics company that develops and commercializes proteomics platforms for analyzing protein concentrations in biological samples such as plasma, serum, CSF, and urine to support drug discovery, biomarker identification, and disease profiling; its core offerings include the proprietary SomaScan Assay, which utilizes slow off-rate modified aptamers (SOMAmers) to measure up to 11,000 unique human protein analytes with high throughput, specificity, and reproducibility in a CLIA-certified lab, custom and disease-specific SomaScan panels for targeted protein profiling, and SomaSignal Tests providing clinically validated insights across more than 20 areas including cardiovascular risk, liver function, metabolic disease, nonalcoholic steatohepatitis, and wellness. Founded in 2000 and headquartered in Boulder, Colorado, the company serves pharmaceutical and biotechnology firms, academic institutions, government researchers, and clinical customers primarily in the United States with global partnerships, having gone public via a SPAC merger in September 2021 before its acquisition by Standard BioTools Inc. in an all-stock deal in January 2024, which operates it as a subsidiary. Recent developments include the expansion of its long-term collaboration with Novo Nordisk through 2025 for proteomics in chronic disease research and drug development, the July 2022 acquisition of DNA nanotechnology firm Palamedrix Inc. to enhance its platform capabilities, and in June 2025, Standard BioTools agreeing to sell SomaLogic and related assets to Illumina, Inc. for $350 million in cash plus up to $75 million in milestones and royalties, building on a prior co-development pact since 2021 to integrate SomaScan with Illumina's next-generation sequencing platforms like NovaSeq X for advanced multiomics applications.
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
Madryn Asset Management Demands SomaLogic's Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting
Madryn Asset Management Addresses SomaLogic's Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools
SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools
Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools
Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures
Leading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools
SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders
Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools
SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure
Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of Alternatives
Madryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw “Cautionary Support” for SomaLogic's Value-Destructive Proposed Merger with Standard BioTools
Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools
Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools
ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools
Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools
SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools
Madryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic's Recent Investor Presentation